Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis

Name: Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis
Creator: Shannon Wongvibulsin
Published: 2021-03-26T22:12:16.936Z
Keywords: Dermatology

Wongvibulsin, Shannon; Pahalyants, Vartan; Kalinich, Mark; Murphy, William; Yu, Kun-Hsing; Wang, Feicheng; Chen, Steven; Reynolds, Kerry; Kwatra, Shawn; Semenov, Yevgeniy

doi:10.17632/8f3tfgbdjx.1

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis

Published: 26 March 2021| Version 1 | DOI: 10.17632/8f3tfgbdjx.1

Contributors:

Shannon Wongvibulsin, Vartan Pahalyants, Mark Kalinich, William Murphy, Kun-Hsing Yu, Feicheng Wang, Steven Chen, Kerry Reynolds, Shawn Kwatra, Yevgeniy Semenov

Description

Supplemental materials for manuscript titled: Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis

Files

Institutions

Harvard Medical School Department of Dermatology

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis

Description

Files

Institutions

Categories

Licence